Avenue Biosciences raises $5.7M to scale the first platform modulating the secretory pathway for enhanced therapeutic protein manufacturing
– Funding will be used to scale the first technology for measuring and modulating the efficacy of the protein secretory pathway, a critical bottleneck affecting the development and manufacturing of therapeutic proteins.
– The Avenue technology generates thousands of versions of a therapeutic protein, outperforming current industry standards in yield and quality.
– This technology enables new, often previously unfeasible, therapeutic targets, for example, in cancer care, infectious diseases, and immunology, to reach patients faster, spanning antibodies, vaccines, AI-designed proteins, gene therapies, and many more.
Palo Alto, California, USA (January 12, 2026) – Avenue Biosciences, a protein engineering technology company, today announced $5.7M in seed extension funding round co-led by Balnord, and Tesi, with support from existing investors Voima Ventures, Inventure, University of Helsinki, and Dimerent, to scale a high-throughput protein engineering technology that accelerates the discovery of protein-based therapies and tools for the biotechnology industry.
The technology uses a library of thousands of naturally occurring and engineered signal peptides to measure the efficiency of protein biogenesis in the secretory pathway – the machinery responsible for folding, modifying, and secreting therapeutic proteins.
